Igc pharma expands calma phase 2 trial with site at lynn health science institute in oklahoma city

Potomac, md / access newswire / august 25, 2025 / igc pharma, inc. (nyse american:igc) today announced the expansion of its ongoing phase 2 clinical trial evaluating igc-ad1, an investigational drug candidate for treating agitation in patients with alzheimer's disease. the company has added a clinical site at the lynn health science institute (lhsi) in oklahoma city, oklahoma.
IGC Ratings Summary
IGC Quant Ranking